Foot and Mouth Disease News and Research RSS Feed - Foot and Mouth Disease News and Research

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec reports net loss of $1.7 million for second quarter 2014

GenVec, Inc. today reported financial results for the three-month and six-month periods ended June 30, 2014. For the three-month period ended June 30, 2014, the company reported a net loss of $1.7 million or $0.10 per share on revenues of $0.1 million as compared to a net loss of $3.1 million or $0.24 per share on revenues of $0.7 million in the same period in the prior year. [More]
Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. [More]
Study reveals new invasion mechanism of Enterovirus 71

Study reveals new invasion mechanism of Enterovirus 71

A new study determines glycosylation and pH-dependent conformational changes of virus receptor SCARB2 as crucial for EV71 attachment, entry and uncoating. [More]
Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. [More]
GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec's revenues decrease 61% to $3.7M in fourth quarter 2013

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013. For the year ended December 31, 2013, the company reported a net loss of $10.0 million, or $0.77 per share, compared with a net loss of $14.1 million, or $1.09 per share, for the year ended December 31, 2012. [More]
Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers discover potential treatment for viral infection that causes illnesses in children

Researchers have discovered a potential treatment for a viral infection that causes potentially fatal brain swelling and paralysis in children. The findings also point to possible treatments for related viruses including those that cause "common cold" symptoms. [More]
First broad-spectrum drugs to combat human rhinoviruses

First broad-spectrum drugs to combat human rhinoviruses

Scientists are reporting progress in the search for the first broad-spectrum drugs to combat human rhinoviruses (HRVs), which cause humanity's most common infectious diseases. [More]
New approach to beef trade could positively transform livelihoods for farmers, reduce threat to wildlife movements

New approach to beef trade could positively transform livelihoods for farmers, reduce threat to wildlife movements

A new study by the Wildlife Conservation Society's Animal & Human Health for the Environment And Development (AHEAD) Program, World Wildlife Fund (WWF), and regional partners finds that a new approach to beef production in southern Africa could positively transform livelihoods for farmers and pastoralists, while helping to secure a future for wildlife and wildlife-based tourism opportunities. [More]
Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility. [More]
Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Clinical data of EV71 vaccine for prevention of HFMD presented at World Vaccine Congress & Expo

Sinovac Biotech Ltd., a leading provider of vaccines in China, announced today that Fengcai Zhu, Deputy Director of the Jiangsu Provincial Center for Disease Prevention and Control, presented data regarding Sinovac's proprietary enterovirus 71 ("EV71") vaccine against hand, foot and mouth disease at the 13th Annual World Vaccine Congress & Expo, taking place from April 16-18, 2013, in Washington D.C. [More]
Australian, Singapore researchers join hands to combat disease-causing bugs

Australian, Singapore researchers join hands to combat disease-causing bugs

The fight against a number of significant infectious diseases in the Asia-Pacific region has been given a boost through a new research collaboration between the National Health and Medical Research Council in Australia and the Agency for Science, Technology and Research in Singapore. [More]
Findings provide structural basis for development of drugs to fight enterovirus 71 infection

Findings provide structural basis for development of drugs to fight enterovirus 71 infection

New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children. [More]
Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine. [More]
New lab at Diamond to help scientists delve into inner workings of pathogens

New lab at Diamond to help scientists delve into inner workings of pathogens

The UK's national synchrotron facility, Diamond Light Source, is now the first and only place in Europe where pathogens requiring Containment Level 3 - including serious viruses such as those responsible for AIDS, Hepatitis and some types of flu - can be analysed at atomic and molecular level using synchrotron light. [More]
Significant increase in genomic Replikin Count of human SARS virus

Significant increase in genomic Replikin Count of human SARS virus

The identification of the virus responsible for a second case of SARS-like respiratory virus, "London1_novel CoV 2012", has raised concerns over the risk of the disease spreading. These concerns may be justified given the observed rise in virus's genomic Replikin Count. [More]
Vitamin A insufficiency linked to hand, foot and mouth disease

Vitamin A insufficiency linked to hand, foot and mouth disease

Vitamin A status is associated with immunity to, and pathogenic condition of, hand, foot, and mouth disease in children, say researchers whose study results show that the majority of those with the infectious disease also had vitamin A insufficiency. [More]
Fatal outcome from HFMD is rare, says LUHS pediatric infectious disease specialist

Fatal outcome from HFMD is rare, says LUHS pediatric infectious disease specialist

A mysterious disease that has killed nearly 60 children in Cambodia has been identified by the World Health Organization as enterovirus 71. This virus is one among a family of viruses that cause a variety of illnesses, including a common childhood illness called hand, foot and mouth disease, but Andrew Bonwit, MD, pediatric infectious disease specialist at Loyola University Health System, says a fatal outcome from such illness is rare. [More]

Enterovirus blamed for some deaths of Cambodian children; Officials continue to investigate mysterious respiratory illness

"Lab tests have confirmed that a virulent strain of hand, foot and mouth disease known as [enterovirus-71 (EV-71)] is to blame for some of the 59 cases of mysterious illness among children in Cambodia reviewed since April, including 52 deaths, according to a joint statement from the World Health Organization and Cambodian Health Ministry," the Associated Press reports, noting that "the numbers were lowered from the initial report of 62 cases." [More]
Sinovac provides update on EV71 vaccine Phase III trial on HFMD

Sinovac provides update on EV71 vaccine Phase III trial on HFMD

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today provided an update on its Phase III clinical trial progress and commercialization preparation for its proprietary inactivated Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD). [More]
Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012. [More]